| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
It is a benzylisoquinoline alkaloid isolated from the Coptidis Rhizoma-Euodiae Fructus couple [1].
|
|---|---|
| ln Vitro |
8-Oxocoptisine (7) showed cytotoxic activity against human gastric carcinoma NCI-N87 cells with an IC50 value of 20.31 ± 3.08 μM. It exhibited poor activity against human colon adenocarcinoma Caco-2 cells (IC50 > 100 μM). Compared to compound 4 (13-carboxaldehyde-8-oxocoptisine), the absence of the aldehyde group at C-13 in 7 tended to enhance the cytotoxic activity against NCI-N87 cells [1].
Compared to Caco-2 (IC50>100 μM), 8-oxocoptisine exhibits no cytotoxicity against NCI-N87 (IC50=20.31 μM)[1]. |
| Cell Assay |
NCI-N87 human gastric carcinoma cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C in 5% CO2. Caco-2 human colon adenocarcinoma cells were cultured in DMEM medium with the same supplements. Cells were seeded into 96-well plates at a density of 1 × 10⁴ cells/well in 100 μL medium. After 24 hours of incubation, cells were treated with 8-oxocoptisine at various concentrations (0.25, 2.5, 10, 25, 50, and 100 μM) and incubated for 48 hours. Subsequently, 20 μL of MTT solution (5 mg/mL) was added to each well, and plates were incubated for another 4 hours. Then, 100 μL of dissolving solution (containing 10% sodium dodecyl sulfate, 5% isopropanol, and 0.1% HCl in water) was added to dissolve the formazan crystals. The optical density was measured at 540 nm using a microplate reader. The vehicle (DMSO) content in the medium never exceeded 1% (v/v), and vehicle control showed no inhibitory effect on cell viability. IC50 values were calculated using Sigmoidal fit. Vinorelbine was used as a positive control drug (IC50 = 12.19 ± 4.33 μM against NCI-N87 cells) [1].
|
| References | |
| Additional Infomation |
8-Oxocoptisine is a known benzylisoquinoline alkaloid isolated from the Coptidis Rhizoma-Euodiae Fructus couple (Zuojin formula, ratio 6:1 w/w). Its structure was identified by comparison of spectral data with reported and authentic standard data. It was obtained as a yellow precipitate from the n-BuOH fraction of the ethanolic extract. The compound has a molecular formula of C₁₉H₁₃NO₆. The 1H NMR spectrum of 7 showed two methylenedioxy groups, a -CH₂-CH₂-N- group, two isolated aromatic protons, and a pair of ortho-coupled aromatic protons [1].
According to reports, 8-oxocorydin has been found in plants of the genus Corydalis ternata, Corydalis yanhusuo, and other organisms with available data. |
| Molecular Formula |
C19H13NO5
|
|---|---|
| Molecular Weight |
335.31
|
| Exact Mass |
335.079
|
| CAS # |
19716-61-1
|
| PubChem CID |
5245667
|
| Appearance |
Light yellow to yellow solid
|
| Density |
1.6±0.0 g/cm3
|
| Boiling Point |
617.5±0.0 °C at 760 mmHg
|
| Flash Point |
327.3±0.0 °C
|
| Vapour Pressure |
0.0±0.0 mmHg at 25°C
|
| Index of Refraction |
1.768
|
| LogP |
4.65
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
25
|
| Complexity |
621
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C([H])([H])OC2=C1C([H])=C1C(=C2[H])C([H])([H])C([H])([H])N2C(C3C4=C(C([H])=C([H])C=3C([H])=C21)OC([H])([H])O4)=O
|
| InChi Key |
UCAFJBSQKXVPDX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H13NO5/c21-19-17-11(1-2-14-18(17)25-9-22-14)5-13-12-7-16-15(23-8-24-16)6-10(12)3-4-20(13)19/h1-2,5-7H,3-4,8-9H2
|
| Chemical Name |
5,7,17,19-tetraoxa-13-azahexacyclo[11.11.0.02,10.04,8.015,23.016,20]tetracosa-1(24),2,4(8),9,15(23),16(20),21-heptaen-14-one
|
| Synonyms |
8-Oxocoptisine; 5,7,17,19-tetraoxa-13-azahexacyclo[11.11.0.02,10.04,8.015,23.016,20]tetracosa-1(24),2,4(8),9,15(23),16(20),21-heptaen-14-one; DTXSID901317158; 5,7,17,19-tetraoxa-13-azahexacyclo(11.11.0.02,10.04,8.015,23.016,20)tetracosa-1(24),2,4(8),9,15(23),16(20),21-heptaen-14-one;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 2.08 mg/mL (6.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9823 mL | 14.9116 mL | 29.8231 mL | |
| 5 mM | 0.5965 mL | 2.9823 mL | 5.9646 mL | |
| 10 mM | 0.2982 mL | 1.4912 mL | 2.9823 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
